BioMedPartners

Founded in 2017, TOLREMO therapeutics is a biotechnology company based in Muttenz, Switzerland. It specializes in developing small molecule therapies to target and eradicate cancer cells that cause drug resistance, aiming to prolong the lives of cancer patients.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, founded in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a critical microRNA responsible for pathological changes in the heart resulting from stress or injury. Through its innovative approach, Cardior Pharmaceuticals seeks to address significant unmet medical needs in cardiovascular health.

Topas Therapeutics GmbH, established in 2013 and based in Hamburg, Germany, is a biotechnology company specializing in the development of nanoparticle-based therapeutics. The company's core focus is to induce antigen-specific immune tolerance, utilizing the liver's natural immunology capabilities to treat autoimmune diseases, allergies, and anti-drug antibodies. Topas' proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells, enabling tolerance against blood-borne antigens. The company has several clinical-stage programs, including TPM203 for pemphigus vulgaris, and collaborations with pharmaceutical giants like Eli Lilly and Boehringer Ingelheim. Topas Therapeutics is backed by prominent investors such as Epidarex Capital, Gimv, EMBL Ventures, Evotec, and Boehringer Ingelheim Venture Fund.

Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.

Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.

Topas Therapeutics GmbH, established in 2013 and based in Hamburg, Germany, is a biotechnology company specializing in the development of nanoparticle-based therapeutics. The company's core focus is to induce antigen-specific immune tolerance, utilizing the liver's natural immunology capabilities to treat autoimmune diseases, allergies, and anti-drug antibodies. Topas' proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells, enabling tolerance against blood-borne antigens. The company has several clinical-stage programs, including TPM203 for pemphigus vulgaris, and collaborations with pharmaceutical giants like Eli Lilly and Boehringer Ingelheim. Topas Therapeutics is backed by prominent investors such as Epidarex Capital, Gimv, EMBL Ventures, Evotec, and Boehringer Ingelheim Venture Fund.

Founded in 2017, TOLREMO therapeutics is a biotechnology company based in Muttenz, Switzerland. It specializes in developing small molecule therapies to target and eradicate cancer cells that cause drug resistance, aiming to prolong the lives of cancer patients.

Aleva Neurotherapeutics SA is a Swiss company specializing in the development of advanced implantable deep brain stimulation (DBS) systems. Founded in 2008 and based in Lausanne, Aleva focuses on creating next-generation neurostimulation devices that utilize microelectromechanical systems (MEMS) technology. Its flagship product, directSTIM, features an array of directional microelectrodes that enable precise electrical stimulation, enhancing the efficacy of DBS therapy for conditions such as Parkinson's disease and essential tremor. In addition, Aleva has developed spiderSTIM, a diagnostic system that maps three-dimensional brain targets to optimize stimulation, and cortiSTIM, designed for cortical stimulation. The company is committed to maximizing the potential of its technology by launching a series of therapeutic products while carefully managing development risks. Aleva Neurotherapeutics is ISO13485 certified, underscoring its dedication to quality and safety in the medical device sector.

Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.

Founded in 2012, Amal Therapeutics is a Swiss biotechnology company focused on developing therapeutic vaccines for oncology using its proprietary cell penetrating peptide platform. Its vaccines aim to activate killer T cells and promote immunological memory, facilitating effective cancer treatment.

Founded in 2017, TOLREMO therapeutics is a biotechnology company based in Muttenz, Switzerland. It specializes in developing small molecule therapies to target and eradicate cancer cells that cause drug resistance, aiming to prolong the lives of cancer patients.

Founded in 2012, Amal Therapeutics is a Swiss biotechnology company focused on developing therapeutic vaccines for oncology using its proprietary cell penetrating peptide platform. Its vaccines aim to activate killer T cells and promote immunological memory, facilitating effective cancer treatment.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, founded in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a critical microRNA responsible for pathological changes in the heart resulting from stress or injury. Through its innovative approach, Cardior Pharmaceuticals seeks to address significant unmet medical needs in cardiovascular health.

Aleva Neurotherapeutics SA is a Swiss company specializing in the development of advanced implantable deep brain stimulation (DBS) systems. Founded in 2008 and based in Lausanne, Aleva focuses on creating next-generation neurostimulation devices that utilize microelectromechanical systems (MEMS) technology. Its flagship product, directSTIM, features an array of directional microelectrodes that enable precise electrical stimulation, enhancing the efficacy of DBS therapy for conditions such as Parkinson's disease and essential tremor. In addition, Aleva has developed spiderSTIM, a diagnostic system that maps three-dimensional brain targets to optimize stimulation, and cortiSTIM, designed for cortical stimulation. The company is committed to maximizing the potential of its technology by launching a series of therapeutic products while carefully managing development risks. Aleva Neurotherapeutics is ISO13485 certified, underscoring its dedication to quality and safety in the medical device sector.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

Curetis AG is a Germany-based company that specializes in developing molecular diagnostics solutions for infectious diseases. Founded in 2015 and now operating as a subsidiary of OpGen, Inc., Curetis focuses on the detection of pathogens and antibiotic resistance markers. The company offers a rapid diagnostic platform that enables multiparameter testing of various analytes in a single run, providing comprehensive panels for detecting a wide range of pathogens and resistance genes. This innovative approach aims to improve patient outcomes by delivering early, actionable information to healthcare providers, particularly in the context of severe bacterial infections. Curetis's technology not only addresses current healthcare challenges but also presents opportunities for future expansions into other clinical applications beyond infectious diseases.

Humedics develops a breath analysis device that measures liver function in real-time. Its LiMAx test enables clinicians to quantitatively determine individual liver function capacity, supporting treatment decisions and improving patient outcomes. The company focuses on applications such as liver transplantation diagnosis, living donor assessment, and disease evaluation.

ImevaX GmbH is a biopharmaceutical company based in Munich, Germany, founded in 2014. The company specializes in developing vaccines targeting pathogens that cause chronic infectious diseases and nosocomial infections. ImevaX's approach involves creating specific vaccines against immune evasion factors used by these pathogens to control infections. Their lead candidate is IMX 101, a vaccine designed to combat Helicobacter pylori, a bacterium that colonizes the stomach and is linked to ulcer disease and gastric cancer in humans. The company’s research focuses on understanding and neutralizing bacterial factors that down-regulate the host immune system, a mechanism used by many highly infectious pathogens. Additionally, ImevaX offers diagnostic tests for early detection of Helicobacter pylori infections.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Aleva Neurotherapeutics SA is a Swiss company specializing in the development of advanced implantable deep brain stimulation (DBS) systems. Founded in 2008 and based in Lausanne, Aleva focuses on creating next-generation neurostimulation devices that utilize microelectromechanical systems (MEMS) technology. Its flagship product, directSTIM, features an array of directional microelectrodes that enable precise electrical stimulation, enhancing the efficacy of DBS therapy for conditions such as Parkinson's disease and essential tremor. In addition, Aleva has developed spiderSTIM, a diagnostic system that maps three-dimensional brain targets to optimize stimulation, and cortiSTIM, designed for cortical stimulation. The company is committed to maximizing the potential of its technology by launching a series of therapeutic products while carefully managing development risks. Aleva Neurotherapeutics is ISO13485 certified, underscoring its dedication to quality and safety in the medical device sector.

Aleva Neurotherapeutics SA is a Swiss company specializing in the development of advanced implantable deep brain stimulation (DBS) systems. Founded in 2008 and based in Lausanne, Aleva focuses on creating next-generation neurostimulation devices that utilize microelectromechanical systems (MEMS) technology. Its flagship product, directSTIM, features an array of directional microelectrodes that enable precise electrical stimulation, enhancing the efficacy of DBS therapy for conditions such as Parkinson's disease and essential tremor. In addition, Aleva has developed spiderSTIM, a diagnostic system that maps three-dimensional brain targets to optimize stimulation, and cortiSTIM, designed for cortical stimulation. The company is committed to maximizing the potential of its technology by launching a series of therapeutic products while carefully managing development risks. Aleva Neurotherapeutics is ISO13485 certified, underscoring its dedication to quality and safety in the medical device sector.

Curetis AG is a Germany-based company that specializes in developing molecular diagnostics solutions for infectious diseases. Founded in 2015 and now operating as a subsidiary of OpGen, Inc., Curetis focuses on the detection of pathogens and antibiotic resistance markers. The company offers a rapid diagnostic platform that enables multiparameter testing of various analytes in a single run, providing comprehensive panels for detecting a wide range of pathogens and resistance genes. This innovative approach aims to improve patient outcomes by delivering early, actionable information to healthcare providers, particularly in the context of severe bacterial infections. Curetis's technology not only addresses current healthcare challenges but also presents opportunities for future expansions into other clinical applications beyond infectious diseases.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

Activaero develops controlled breathing technologies for efficient pulmonary delivery of inhaled therapeutics. Its flagship product, AKITA, uses smart card technology to enable safe and precise local drug deposition in the lungs, targeting conditions such as asthma, COPD, cystic fibrosis, and idiopathic pulmonary fibrosis.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Evolva is a Swiss biotechnology company that develops and commercializes nature-based ingredients using synthetic biology. Founded in 2004, Evolva's proprietary platform enables the creation of innovative small-molecule drugs and compounds inspired by natural products but without their inherent limitations.

Curetis AG is a Germany-based company that specializes in developing molecular diagnostics solutions for infectious diseases. Founded in 2015 and now operating as a subsidiary of OpGen, Inc., Curetis focuses on the detection of pathogens and antibiotic resistance markers. The company offers a rapid diagnostic platform that enables multiparameter testing of various analytes in a single run, providing comprehensive panels for detecting a wide range of pathogens and resistance genes. This innovative approach aims to improve patient outcomes by delivering early, actionable information to healthcare providers, particularly in the context of severe bacterial infections. Curetis's technology not only addresses current healthcare challenges but also presents opportunities for future expansions into other clinical applications beyond infectious diseases.

Activaero develops controlled breathing technologies for efficient pulmonary delivery of inhaled therapeutics. Its flagship product, AKITA, uses smart card technology to enable safe and precise local drug deposition in the lungs, targeting conditions such as asthma, COPD, cystic fibrosis, and idiopathic pulmonary fibrosis.

Evolva is a Swiss biotechnology company that develops and commercializes nature-based ingredients using synthetic biology. Founded in 2004, Evolva's proprietary platform enables the creation of innovative small-molecule drugs and compounds inspired by natural products but without their inherent limitations.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Lumavita AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development and commercialization of novel anti-infectives aimed at women's health. Founded in 2008, Lumavita focuses on addressing infections that affect women, with key products including FemiFect, an antibiotic designed to treat vaginitis caused by various pathogens, and SPK-601, which targets human papilloma virus (HPV) and herpes simplex virus (HSV). The company operates as a subsidiary of Shogoo Pharmaceuticals KK and distributes its products through a network of distributors. Lumavita AG was previously known as Shogoo Pharmaceuticals, AG before rebranding in 2007.

Vivendy Therapeutics Ltd. is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative treatments for rare lysosomal storage diseases. Founded in 2006, the company is primarily engaged in creating an enzyme replacement therapy for Morbus Morquio, also known as MPS IVA, which is caused by a deficiency in a specific enzyme. Vivendy has developed a recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that has been specifically modified to enhance enzyme activity, significantly improving the efficacy of the therapy. Through its research and development efforts, Vivendy Therapeutics aims to address the unmet medical needs of patients suffering from this rare condition.

Idiag AG is a Swiss company that specializes in designing, manufacturing, and marketing healthcare equipment aimed at improving health and performance. Founded in 1993 and based in Fehraltorf, the company offers a range of products, including SpinalMouse for back assessments, STMedical for respiratory therapy, SpiroTiger for respiratory training, and the Biacorpus RX 4000 for body composition analysis. Additionally, Idiag provides solutions for weight management, spinal analysis, and therapy, catering to a diverse clientele that includes doctors, physiotherapists, medical personnel, and both professional and recreational athletes. The company focuses on converting innovative medical technology ideas into market-ready products, collaborating with universities and innovation centers for development and marketing. Idiag markets its products through dealers in Switzerland, Germany, and other international markets, leveraging its resources and networks for effective sales and market penetration.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to developing and marketing innovative treatments for mitochondrial and neuromuscular diseases, areas with significant unmet medical needs.

Dolthera GmbH is a biopharmaceutical company that is developing an innovative class of nucleic-acid-based anti-inflammatory drugs. These drugs, based on oligonucleotides that act as decoys for disease-related transcription factors are all directed against biologically validated targets in major chronic diseases with high unmet medical need. With this business concept and the underlying patent-protected technologies, AVONTEC won in 2003 the prestigious German Founders Award that is backed by McKinsey & Company. Initially, the Company has chosen to focus its patented technology on chronic inflammatory respiratory system and skin diseases. AVONTEC currently has five programs in respiratory disease, skin disease, transplant rejection, cardiovascular disease and autoimmune disease under development. All these indications represent areas with high unmet medical need and strong commercial potential.

Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies. The company focuses on improving patient care and safety through its proprietary Acurate™ Aortic Valve Replacement System, which features a unique self-positioning design. This design allows for easier implant positioning and alignment, enhancing the overall user experience for healthcare providers. Symetis aims to address the needs of patients suffering from aortic valve stenosis, enabling the effective treatment of severe cardiac valve conditions through its advanced transcatheter aortic valve implantation devices.

Thommen Medical is a medical device company that specializes in the development, production, and sale of dental implants, marketed under the brand name SPI (Swiss Precision Implant). The company focuses on creating innovative and well-designed implant systems that enhance patient comfort during procedures and ensure long-term stability of the implants. Thommen Medical collaborates with leading scientific and dental clinicians to ensure that its products meet high standards of precision and usability. In addition to dental implants, the company also offers biomaterial solutions aimed at bone and tissue regeneration, further contributing to advancements in dental health and restoration.